Cefpodoxime
PreclinicalSmall molecule
Cefpodoxime is one of 33 small molecule programs targeting Cystitis. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
51 competitors in Cystitis
#DrugCompanyPhaseTrials
1Ivadantin
PProcter and Gamble
Approved
Monurol
MMeitheal
Approved
Oxytrol
WWim Janssens
Approved
Advil
KKenvue Brands
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Cipro
BayerPhase 3
Antibiotics
MMelinta Therapeutics, Inc.
Approved
Chibroxin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Spectracef
Alnylam PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cefpodoxime. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details